Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells

S. Auletta, V. Iodice, F. Galli, N. Lepareur, A. Devillers, and A. Signore

1 Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, “Sapienza” University of Rome, Italy
2 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Netherlands
3 Nuclear Medicine Department, Centre Eugene Marquis, Université Européen de Bretagne, Rennes Cedex, France

Correspondence should be addressed to A. Signore; alberto.signore@uniroma1.it

Received 2 July 2018; Accepted 1 October 2018; Published 25 October 2018

Copyright © 2018 S. Auletta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nuclear medicine offers several techniques and procedures to image infection, but radiolabelled autologous white blood cells (WBCs) are still the gold standard. These cells are usually labelled with 111In or 99mTc bound to a hydrophobic chelating agent that allows these isotopes to pass through the plasma membrane and enter in the cytoplasm. The most common compound in Europe is HMPAO that efficiently chelates 99mTc. However, up to 20–40% of the complex is released from the cells in the first few hours. The aim of this study was to radiolabel a new compound, (S2CPh)2(S3CPh)-complex (SSS-complex) with 99mTc and compare its binding kinetics and specificity for WBC with HMPAO. The SSS-complex was labelled with 99mTc and analysed by iTLC and RP-HPLC. In vitro quality controls included a stability assay in serum and saline. Results showed a labelling efficiency of 95 ± 1.2% and 98 ± 1.4% for 99mTc-SSS-complex and 99mTc-HMPAO, respectively (p = ns). 99mTc-SSS-complex was stable in serum and in saline up to 24 h (94 ± 0.1%). Cell labelling experiments showed a higher incorporation of 99mTc-SSS-complex and 99mTc-HMPAO, respectively (p = ns). 99mTc-SSS-complex was stable in serum and in saline up to 24 h (94 ± 0.1%). Cell labelling experiments showed a higher incorporation of 99mTc-SSS-complex than 99mTc-HMPAO by granulocytes (62.6 ± 17.8% vs 40.5 ± 15%, p = 0.05). 99mTc-SSS-complex and 99mTc-HMPAO by granulocytes (62.6 ± 17.8% vs 40.5 ± 15%, p = 0.05). Lymphocytes (59.9 ± 22.2% vs 29.4 ± 13.5%; p = 0.03), and platelets (44.4 ± 24% vs 20.5 ± 10.7%; p = ns), but the release of radiopharmaceutical from granulocytes at 1 h was lower for HMPAO than for SSS-complex (10.3 ± 19.9% vs 21.3 ± 18.8%; p = 0.001). In conclusion, 99mTc-SSS-complex, although showing high labelling efficiency, radiochemical purity, and stability, is not a valid alternative to 99mTc-HMPAO, for example, in vivo white blood cells labelling because of high lymphocyte and platelet uptake and rapid washout from granulocytes.

1. Introduction

The early and accurate localization of infectious foci and inflammation is a major challenge in contemporary nuclear medicine. In 1970s, a method for imaging of infections/inflammation, based on the ex vivo labelling of autologous leukocytes with Indium-111 (111In), was developed by Thakur and colleagues [1–3]. However, 111In showed some drawbacks like poor image quality, unfavorable dosimetry, and cell toxicity, in particular on the white blood cell (WBC) subsets [4–6].

Therefore, new methodologies were developed to replace 111In with 99mTc for ex vivo cell labelling, and in 1986, 99mTc-HMPAO entered in clinical practice for WBC radiolabelling and imaging of occult sites of infection [7]. 99mTc-HMPAO is less toxic than 111In-oxine to WBC, providing a better image quality and isotope availability. However, if not completely reduced intracellularly, it may be released from cells with time, especially in those patients with impaired redox metabolism (hypovitaminosis, stress, metabolic diseases, drugs, etc.).

Other several agents were tested as an alternative to HMPAO to label WBC. In 90s, ethyl cysteinate dimer (ECD) and d,l-cyclobutlyphene amine oxime (d,l-CBPAO) were labelled with 99mTc, and their labelling efficiency and stability were compared with 99mTc-HMPAO. Both showed higher radiochemical purity than 99mTc–HMPAO, but only 99mTc-d,l-CBPAO provided a comparable binding to WBC.
Despite being reported as a valid alternative to $^{99m}$Tc-HMPAO, it did not find its place in clinical practice [8, 9]. Pasqualini et al. in 2002 patented $[^{99m}\text{Tc}(\text{S}_2\text{CPh})_2(\text{S}_2\text{CPh})]$(SSS-complex) as a new radiopharmaceutical product for selective labelling of WBC, and in 2003, Mevellec et al. published its synthesis using different methods [10, 11]. They demonstrated that the most efficient labelling method was based on the reaction of a lyophilized formulation of $^{99m}\text{Tc}$-gluconate with the sodium salt of phenylthiocarboxylic acid. However, no systematic studies have ever been published to show the binding kinetics and specificity of this complex.

Therefore, in the present study, we performed the radiolabelling with $^{99m}$technetium of SSS-complex and tested its radiochemical purity, stability, binding specificity, and kinetics to different blood cell subsets as compared to $^{99m}$Tc-HMPAO.

2. Materials and Methods

2.1. Radiolabelling of SSS-Complex. A technetium-99m reducing kit, containing 4 mg of thin chloride dihydrate, 30 mg of sodium gluconate, 40 mg of potassium oxalate, and 30 mg of ascorbic acid, was reconstituted with 10 ml of saline solution, and 1 ml of this solution was added to freshly eluted $^{99m}\text{TcO}_4^-$ (370–720 MBq). The mixture was gently stirred for 10 min at room temperature, and then, 8–10 mg of SSS-complex in 1 ml of saline solution was added. After 15 min of incubation at 100°C, labelling efficiency (LE) and colloid percentages were measured.

2.2. In Vitro Quality Controls. Quality controls were performed using both instant thin layer chromatography (i TLC) and reversed phase-HPLC (RP-HPLC). For iTLC, silica-gel strips were used as stationary phase (Pall Life Sciences, Port Washington, NY), whereas a 0.5 M ethanol/toluene/chloroform/ammonium acetate 6:3:3:1 solution was used as mobile phase. In these conditions, it was possible to differentiate pertechnetate ($R_f$ = 0.5) and the intermediate gluconate complex ($R_f = 0$). A mixture of petroleum ether and dichloromethane (6:4) was used as the mobile phase to perform quality controls of the $^{99m}\text{Tc}$-SSS-complex ($R_f = 0.7$). The strips were analyzed by a radio-scanner (Bioscan, Inc, Poway, CA) to calculate the LE. The complex was also analyzed by RP-HPLC using a C18 column (5 mm, 5 μm, 250 × 4.6 mm, Phenomenex, Torrance, CA) and the following mobile phase: H$_2$O and THF gradient (0–3 min 70% H$_2$O; 3–17 min 100% THF; 17–30 min 70% H$_2$O) with a flow rate of 1 ml/min.

Stability assays were performed adding 100 μl of $^{99m}\text{Tc}$-SSS-complex to 900 μl of fresh human blood serum or to 900 μl of 0.9% saline solution. The vials were incubated up to 24 h at 37°C. The LE was measured at 1, 3, 6, and 24 h by iTLC [12].

2.3. Radiolabelling of White Blood Cells with $^{99m}$Tc-SSS-Complex. To evaluate SSS-complex specificity for WBC, whole blood from 4 healthy volunteers (40 ml) was collected and mixed with anticoagulant citrate dextrose ACD (8 ml). The blood was stratified in a centrifuge tube containing 20 ml of lympholyte® (Cedarlane). The vial was centrifuged at 500 g for 20 min at room temperature. After centrifugation, platelets, mononuclear cells (MNCs), red blood cells (RBC), and polymorphonuclear cells (PMNCS) were separated as described in the guidelines [13, 14]. Purity of each cell population was determined by FACS analysis. Platelets, MNCs, and PMNCS (16 × 10$^6$ cells) were separately collected and incubated with $^{99m}\text{Tc}$-SSS-complex (74 MBq) under gentle stirring for 10 min at 37°C. Free $^{99m}$Tc-SSS-complex was removed by centrifugation at 600 g for 10 min and washing with PBS. Cell-bound and free radioactivity was determined by counting the pellet and the supernatant, respectively. The labelling yield was calculated as 100$^\circ$MBq pellet/MBq pellet + MBq supernatants. $^{99m}$Tc-HMPAO-WBC were prepared as described by EANM guidelines and used as control [13].

2.4. Stability Assay. Stability of labelled cells was assessed incubating granulocytes, lymphocytes, and platelets in PBS at 37°C. After 1 h and 3 h, an aliquot from each vial was centrifuged to collect pellet and supernatant that were counted for radioactivity with a single-well gamma counter (Atomlab 500, Biodex) in order to evaluate the radiopharmaceutical elution from labelled cells over time.

The trypan blue exclusion test was also performed in order to verify the viability of each cell population at different time points after labelling.

3. Results

3.1. Labelling of SSS-Complex. The labelling efficiency of $^{99m}\text{Tc}$-SSS-complex was >95%, as assessed by both iTLC and RP-HPLC analysis (Figure 1). In particular, the area below the curve of free $^{99m}$Tc is 1.8% at iTLC and 4.2% at HPLC. The resulting labelled complex was highly stable in both human serum and saline up to 24 h (94 ± 0.1%) (Figure 2).

3.2. Cell Separation and Labelling Technique. FACS analysis revealed a good separation of each blood cell subset, with a purity of >90%. A statistically significant higher accumulation of $^{99m}\text{Tc}$-SSS-complex was observed in each subpopulation as compared to $^{99m}$Tc-HMPAO after cell labelling (Figure 3). $^{99m}$Tc-SSS-complex did not show selectivity for any particular blood cell subset as well as $^{99m}$Tc-HMPAO. In particular, granulocytes were labelled with 62.6 ± 17.8% efficiency with $^{99m}$Tc-SSS-complex and 40.5 ± 15% efficiency with $^{99m}$Tc-HMPAO (p = 0.05); lymphocytes were labelled with 59.9 ± 22.2% efficiency with $^{99m}$Tc-SSS-complex and 29.4 ± 13.5% efficiency with $^{99m}$Tc-HMPAO (p = 0.03); finally, platelets were labelled with 44.4 ± 24% efficiency with $^{99m}$Tc-SSS-complex and 20.5 ± 10.7% efficiency with $^{99m}$Tc-HMPAO (p = ns).

Regarding $^{99m}$Tc-SSS-complex, retention experiments showed a rapid decrease of radioactivity in each cell population after 1 h (21.3 ± 1.8%, 40.9 ± 1.96%, and 58.1 ± 33.3%, respectively, for granulocytes, lymphocytes, and platelets), with a further washout up to 3 h (38.6 ± 13.8%, 75.8 ± 10.5%, and 87.6 ± 10.1%, respectively, for granulocytes, lymphocytes,
and platelets). 99mTc-HMPAO shows a slower washout from each cells subset at each time point (Figure 4). Particularly, 99mTc-HMPAO showed the following values of washout:

\[
\begin{align*}
&99mTc \text{- Granulocytes: } 10.3 \pm 1.9\% \ (p < 0.001), \\
&99mTc \text{- Lymphocytes: } 41.6 \pm 18.5\%, \\
&99mTc \text{- Platelets: } 63.3 \pm 9.1\%, \\
&99mTc \text{- Granulocytes: } 18.9 \pm 1.6\% \ (p < 0.05), \\
&99mTc \text{- Lymphocytes: } 42.2 \pm 15.4\% \ (p < 0.005), \\
&99mTc \text{- Platelets: } 67.4 \pm 6.8\% \ (p < 0.003),
\end{align*}
\]

respectively, for granulocytes, lymphocytes, and platelets at 1 h, and 18.9 ± 1.6% (p < 0.05), 42.2 ± 15.4% (p < 0.005), and 67.4 ± 6.8% (p < 0.003) at 3 h for granulocytes, lymphocytes, and platelets, respectively.

Labelling of cell subsets with 99mTc-SSS-complex showed no cell toxicity, with more than 99 ± 0.4% viable cells after 24 h.

4. Discussion

The development of radiopharmaceuticals to distinguish sterile inflammation from infection is still an open challenge, and it is crucial for the diagnosis of various bone and soft tissue diseases, including osteomyelitis, diabetic foot, immune bowel diseases (IBD), and fever of unknown origin (FUO) too. According to international standardized guidelines, 99mTc-HMPAO-WBC or 111In-oxine-WBC are the gold standard to image infection because of their high specificity and rapid clearance from lungs and blood [13, 14]. They specifically accumulate in infectious foci where a neutrophilic infiltrate predominates as a result of migration through the endothelium and basal membrane [15–17]. When using 111In-oxine or 99mTc-HMPAO for WBC labelling, a portion of lymphocytes are also radiolabelled. Since lymphocytes are very sensitive to radiation damage [18], it would be ideal to have a Tc-chelating agent that will selectively label only granulocytes in a mixed WBC suspension.

Therefore, the aim of our study was to investigate the properties of a novel compound for granulocyte labelling: the SSS-complex. This was radiolabelled with 99mTc and compared with HMPAO. The labelling procedure of SSS-complex showed a >95% LE with negligible amount of 99mTc-colloids and high stability in both human serum and 0.9% NaCl solution.
When compared to $^{99m}$Tc-HMPAO for WBC labelling, we found a higher labelling efficiency of $^{99m}$Tc-SSS-complex with respect to $^{99m}$Tc-HMPAO for granulocyte, lymphocyte, and platelet labelling (Figure 3). But washout from these cells was much faster than $^{99m}$Tc-HMPAO in all cell populations, reaching 38.6±13.8% of washout from granulocytes at 3 h (Figure 4).

Indeed, granulocytes labelled with $^{99m}$Tc-HMPAO showed a retention of radioactivity of 90% at 1 h and of 80% at 3 h versus only 80% and 61%, respectively, when labelled with $^{99m}$Tc-SSS-complex. Washout from lymphocytes and platelets was similar at 1 h between the two radiopharmaceuticals, but higher for $^{99m}$Tc-SSS-complex at 3 h in both cell subsets.

Based on these results, it appears that $^{99m}$Tc-SSS-complex cannot substitute $^{99m}$Tc-HMPAO for selective labelling of granulocytes. It enters into all cell subsets, and most importantly, it is ejected from granulocytes in a higher percentage than $^{99m}$Tc-HMPAO. This behavior may affect image quality in vivo.

In an attempt to find a better agent for WBC labelling, Capriotti et al. compared $^{99m}$Tc-HMPAO and $^{99m}$Tc-stannous colloids in 2004 [19]. In this study, $^{99m}$Tc-HMPAO showed a lower and significant spontaneous radioactivity release at different time points in all subjects studied, confirming it as the best choice to label WBC.

WBCs were also labelled with $^{99m}$Tc-liposomes [20] and with $^{99m}$Tc-P483H [21]. Radiolabelled liposomes showed a minimum release after washings at 2 and 6 h, while $^{99m}$Tc-P483H showed a radioactivity associated with WBC equal to 76.5%, both obtaining better results than $^{99m}$Tc-SSS-complex but similar to those achievable with $^{99m}$Tc-HMPAO.

Since there are no other Tc-chelating agents available for WBC labelling, the only alternative consists in the use of antigranulocyte antibodies [22–24], leaving open doors to the study of new radiopharmaceuticals for bacterial imaging, although radiopharmaceuticals synthetized until now showed several limitations [25, 26].
5. Conclusion

$^{99m}$Tc-SSS-complex, although labels white blood cells with high efficiency, showed no selectivity for any particular cell subset, and as the main limiting factor, it showed a high spontaneous release from granulocytes over time. Therefore, in conclusion, $^{99m}$Tc-SSS-complex cannot be considered as a valid alternative to $^{99m}$Tc-HMPAO to label granulocytes for in vivo use as an infection seeking agent.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors wish to acknowledge the Nuclear Medicine Discovery Association for providing financial support for this study. Dr. Sveva Auletta and Dr. Filippo Galli were supported through grants from "Sapienza" University of Rome, Department of Medical-Surgical Sciences and of Translational Medicine.

References

[1] A. W. Segal, R. N. Arnot, M. L. Thakur, and J. P. Lavender, “Indium-111-labeled leucocytes for localization of abscesses,” The Lancet, vol. 13, pp. 1056–1058, 1976.

[2] M. L. Thakur, R. E. Coleman, and M. J. Welch, “Indium-111-labeled leucocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs,” Journal of Laboratory and Clinical Medicine, vol. 89, pp. 217–228, 1977.

[3] M. L. Thakur, J. P. Lavender, R. Arnot, D. J. Silvester, and A. W. Segal, “Indium-111-labeled autologous leucocytes in man,” Journal of Nuclear Medicine, vol. 18, pp. 1012–1019, 1977.

[4] A. Signore, P. Beales, and M. Sensi, “Labelling of lymphocytes with indium 111 oxine: effect on cell surface phenotype and antibody-dependent cellular cytotoxicity,” Immunology Letters, vol. 6, pp. 151–154, 1983.

[5] P. Pozzilli, A. Signore, and C. Pozzilli, “Detrimental effect of indium-111 on human lymphocytes,” Journal of Nuclear Medicine, vol. 25, p. 830, 1984.

[6] E. P. Balaban, T. R. Simon, and E. P. Frenkel, “Toxicity of indium-111 on the radiolabeled lymphocyte,” Journal of Nuclear Medicine, vol. 28, pp. 229–233, 1987.

[7] A. M. Peters, H. J. Danpure, S. Osman et al., “Clinical experience with $^{99m}$Tc-hexamethylpropyleneamine oxime for labeling leucocytes and imaging inflammation,” The Lancet, vol. 328, no. 8513, pp. 946–949, 1986.

[8] C. H. Kao, W. T. Huang, Y. L. Wang, K. S. Lin, J. M. Lo, and S. J. Wang, “A comparative study of $^{99}$Tc-HMPAO and $^{99}$Tc-ECD as a leucocyte labelling agent,” Nuclear Medicine Communications, vol. 15, no. 4, pp. 294–297, 1994.

[9] C. S. Tsai, C. H. Kao, S. J. Yeh, and S. J. Wang, “A comparative study of $^{99}$Tc-d,l-HMPAO and $^{99}$Tcm-d,l-CBPAO as leukocyte-labelling agents,” Nuclear Medicine Communications, vol. 17, no. 1, pp. 76–79, 1996.

[10] R. Pasqualone, E. Bellande, N. Noiret, A. Roucoux, H. Patin, and F. Mevellec, Radiopharmaceutical Products Suitable for The Selective Labeling of Lymphocytes, and their Preparation, International Publication Number: WO 01/90114 A1; 2002; International Application Number: PCT/IB01/00825, 2002.

[11] F. Mevellec, A. Roucoux, N. Noiret, A. Moisan, H. Patin, and A. Duatti, “Synthesis and characterization of new $^{99m}$Tc radiopharmaceuticals with dithiobenzeneo derivatives for the study of septic inflammatory processes,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 46, no. 4, pp. 319–331, 2003.

[12] E. Garin, N. Noiret, C. H. Malbert et al., “Development of $^{99m}$Tc labelled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pig,” Nuclear Medicine Communications, vol. 25, no. 3, pp. 291–297, 2004.

[13] E. F. J. de Vries, M. Roca, F. Jamar, O. Israel, and A. Signore, “Guidelines for the labelling of leukocytes with $^{99m}$Tc-HMPAO,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 4, pp. 842–848, 2010.

[14] M. Roca, E. F. J. de Vries, F. Jamar, O. Israel, and A. Signore, “Guidelines for the labelling of leukocytes with $^{111}$In-oxine,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, pp. 835–841, 2010.

[15] L. Brammen, C. Palestro, and H. Sinzinger, “Radionuclide imaging: past, present and future outlook in the diagnosis of infected prosthetic joints,” Hellenic Journal of Nuclear Medicine, vol. 18, pp. 95–102, 2015.

[16] A. Notopoulos, C. Likartis, E. Zaromytidou et al., “The diagnostic performance of $^{99m}$Tc-HMPAO radiolabelled leucocytes scintigraphy in the investigations of infection. A single center experience,” Hellenic Journal of Nuclear Medicine, vol. 18, pp. 23–28, 2015.

[17] P. A. Erba, A. W. J. M. Glaudemans, N. C. Veltman et al., “Image acquisition and interpretation criteria for $^{99m}$Tc-HMPAO-labelled white blood cell scintigraphy; results of a multicentre study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 4, pp. 615–623, 2014.

[18] A. Signore and A. W. J. M. Glaudemans, “The molecular imaging approach to image infections and inflammation by nuclear medicine techniques,” Annals of Nuclear Medicine, vol. 25, no. 10, pp. 681–700, 2011.

[19] G. Capriotti, C. D’Alessandria, E. Garin et al., “An in vitro study to compare $^{99m}$Tc-stannous colloids and $^{99m}$Tc-HMPAO for labelling human leukocytes,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 48, pp. 229–236, 2004.

[20] D. Andreopoulos, L. P. Kasi, J. Asimacopoulos et al., “Selective in vitro labeling of white blood cells using $^{99m}$Tc-labeled liposomes,” Nuclear Medicine and Biology, vol. 29, no. 2, pp. 185–190, 2002.

[21] B. R. Moyer, S. Vallabhadrosa, J. Lister-James et al., “Technetium-99m-White blood cell-specific imaging agent developed from platelet factor 4 to detect infection,” Journal of Nuclear Medicine, vol. 37, pp. 673–679, 1996.

[22] S. Gratzi, T. Behr, A. Herrmann et al., “Intrathymic analysis of $^{99m}$Tc-labelled anti-SSEA-1 antigranulocyte antibody and $^{99m}$Tc-HMPAO labelled white blood cells for the imaging of infection,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 25, pp. 386–393, 1998.

[23] M. Sollini, C. Lauri, R. Boni, E. Lazzeri, P. A. Erba, and A. Signore, “Current status of molecular imaging in...
infections,” *Current Pharmaceutical Design*, vol. 24, no. 7, pp. 754–771, 2018.

[24] C. Malherbe, A. C. Dupont, S. Maia et al., “Estimation of the added value of 99mTc-HMPAO labelled white blood cells scintigraphy for the diagnosis of infectious foci,” *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, 2017, In press.

[25] S. Auletta, F. Galli, C. Lauri, D. Martinelli, I. Santino, and A. Signore, “Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: a systematic review,” *Clinical and Translational Imaging*, vol. 4, no. 4, pp. 229–252, 2016.

[26] S. Auletta, D. Baldoni, M. Varani et al., "Comparison of $^{99m}$Tc-UBI 29-41, $^{99m}$Tc-ciprofloxacin, $^{99m}$Tc-ciprofloxacin di-thiocarbamate and $^{111}$In-biotin for targeting experimental *Staphylococcus aureus* and *Escherichia coli* foreign-body infections: an ex-vivo study," *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, vol. 26, 2017.
Submit your manuscripts at
www.hindawi.com